CNSP News and Press, CNS Pharmaceuticals Inc. From 08/12/22

Cancer is one of the deadliest diseases on the planet. It affects millions of people across the world, takes more than 10 million lives every year , and still doesn’t have a cure. Most cancer-management therapies involve treatments such as chemotherapy, surgery, radiation therapy and...

CNS Pharmaceuticals (NASDAQ: CNSP) is currently recruiting patients for a phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating glioblastoma multiforme (“GBM”), the most aggressive, deadly and treatment-resistant type of cancer t...

New research has found that a ketogenic diet is feasible and safe for individuals with astrocytomas. A ketogenic diet is low in carbohydrates and high in fat. Astrocytomas are brain tumors that usually begin in cells known as astrocytes , which support nerve cells and occur in the brain o...

CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system The company’s lead candidate is an anthr...

CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, ...

Scientists at Massachusetts General Hospital have developed a tool that can detect additional mutations to help improve tumor diagnosis and monitoring. The scientists, who have in the past created a blood test to detect mutations in a glioma-linked gene, published their findings in “...

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today urged shareholders to vote in favor of the proposals outlined in its definitiv...

CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022 PR Newswire Company reiterates support of proposals for the authorization to increase number of shares available for issuance by ...

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial...

A new study has found an alternative approach that would make immunotherapy treatments more effective when treating brain tumors. Immunotherapy drugs are usually used to treat a range of cancers. However, glioblastoma multiforme, which is a fatal type of cancer, remains resistant to this r...